A new biotech manufacturing facility will be built at the Melbourne Airport Business Park.
Seqirus, a subsidiary of Victorian-based global biopharmaceutical leader CSL, will invest more than $800 million to build the state-of-the-art facility which is expected to open in 2026.
The project is a significant investment in Australia by CSL and will position Victoria at the forefront of the global influenza vaccine market.
It will be the only cell-based influenza vaccine manufacturing facility in the southern hemisphere and the facility will also produce other life-saving products for the Australian market such as the world’s only Q-Fever vaccine and anti-venom for local snakes, spiders and marine creatures.
The new facility will produce seasonal influenza vaccines for use globally and have the capacity to rapidly scale up vaccine production in response to any future influenza pandemic and guarantee the nation with a priority supply.
The project will secure more than ,000 local jobs, generate export contracts and ensure continuing support for hundreds of organisations estimated to be worth $300 million to the local supply chain, helping to boost the state’s economic recovery.
CSL already has a manufacturing plant in Broadmeadows, where they are producing two COVID-19 vaccines.
State minister for Industry Support and Recovery Martin Pakula said the state government is proud to have provided significant support to secure the facility for Melbourne.
“This investment is a significant coup for Victoria. It positions the state as a global leader in cell-based influenza vaccine production and further boosts our capabilities in R&D, commercialisation and advanced manufacturing.”
Seqirus general manager Stephen Marlow said they were excited to work with Victoria’s world-class talent to deliver the next generation of influenza vaccine technology to Australia.”